Gilead’s inhaled version of remdesivir (Veklury) could add considerable value to the COVID-19 market. Potentially, the drug could be used in an outpatient ambulatory setting, assuming clinical trials indicate positive results and regulatory acceptance. Gilead’s success with remdesivir has been undeniably closing nearly 3 billon in less than its first year of its existence. With the drug’s status as the only FDA approved drug for COVID-19, it’s used in 50% of hospitalized COVID-19 cases in America. Sales in 2021 should range from $2 billion to $3 billion, reported CFO Andy Dickinson recently.
The inhaled version of this drug, formulated as a drug-device combination product, acts differently than the injected version of the therapy used in the hospital setting. Given the different mode of action the actual clinical efficacy must be evidenced in randomized controlled trials. The hope is that the drug would be inhaled, possibly post contact with someone with COVID-19 but pre-hospitalization. Still in Phase 1 clinical trial, this effort has a ways to go prior to any possibility for emergency use authorization. TrialSite refers to a recent entry from the San Francisco Business Times.